GlaxoSmithKline (GSK), one of the UK's largest pharmaceutical companies, has made a major move into the lucrative cancer treatment market with a massive $10.6 billion acquisition. In his first major deal since taking over as CEO, Luke Miels has agreed to buy Nuvalent, a Boston-based company specializing in cancer treatments, including three drugs for lung cancer. The FTSE 100 company is betting big on the oncology portfolio, seeking to expand its presence in this high-growth area. The deal is a significant expansion of GSK's capabilities in cancer treatment and could have major implications for patients and investors alike.
British drugmaker’s new chief executive Luke Miels announces one of its biggest dealsBusiness live – latest updatesGSK’s new boss Luke Miels has struck one of the British drugmaker’s biggest deals, announcing the $10.6bn (£7.9bn) acquisition of a US cancer specialist with two-late stage medications.The FTSE 100 company is boosting its oncology portfolio by agreeing to buy Nuvalent, a Boston-based company that develops cancer drugs, including three for lung cancer. Continue reading...
